MSCP EXAM PREP 2026: Board-
Certified Practice Questions with
Clinical Rationales — The Menopause
Society Certification Guide
PHYSIOLOGY & PATHOPHYSIOLOGY (Questions 1-50)
Question 1
A 52-year-old woman presents with persistent moderate hot flashes and
night sweats. She had a hysterectomy 5 years ago. She is currently on oral
conjugated equine estrogens (CEE) 0.3 mg daily but reports inadequate
symptom control. What is the most appropriate management?
A) Switch to transdermal estradiol 0.025 mg patch
B) Discontinue estrogen and start a selective serotonin reuptake inhibitor
C) Increase the daily estrogen dose
D) Add oral micronized progesterone 100 mg daily
Answer: C
Rationale: The patient is on the lowest FDA-approved dose of CEE (0.3 mg).
With persistent symptoms despite adequate treatment duration (typically
4-8 weeks), dose escalation is appropriate. The 0.3 mg dose may be
insufficient for symptom control in some women. Since she had a
hysterectomy, no progestogen is needed, simplifying dose adjustment .
,Question 2
Which agent is the best FDA-approved non-hormonal treatment for
moderate-to-severe vasomotor symptoms in a 55-year-old woman with a
history of estrogen receptor-positive breast cancer?
A) Venlafaxine
B) Gabapentin
C) Paroxetine
D) Black cohosh
Answer: C
Rationale: Systemic estrogen is contraindicated in breast cancer survivors.
Paroxetine 7.5 mg (Brisdelle) is FDA-approved specifically for VMS and is a
non-hormonal option with demonstrated efficacy. SSRIs/SNRIs are
preferred non-hormonal alternatives for breast cancer survivors; however,
paroxetine has the specific FDA approval for this indication .
Question 3
According to the Menopause Society guidelines, which strategy helps
reduce venous thromboembolism (VTE) risk in women using hormone
therapy?
A) Use low-dose oral estrogen
B) Use transdermal estrogen instead of oral
C) Add aspirin to the regimen
D) Use only progestogen therapy
Answer: B
Rationale: Transdermal estrogen avoids first-pass hepatic metabolism, has
lower impact on coagulation factors, and is associated with lower VTE risk
,compared to oral estrogen. VTE risk is dose-dependent and transdermal
routes are especially important in women with other VTE risk factors .
Question 4
A 46-year-old woman with a history of hysterectomy (ovaries remain)
presents with pain with intercourse but no other menopausal symptoms.
What is the best treatment?
A) Systemic hormone therapy with estrogen plus progestogen
B) Oral ospemifene
C) Intravaginal estrogen only
D) Systemic estrogen alone
Answer: C
Rationale: Symptoms are localized with no VMS. Ovaries remain, so
estrogen production continues. Intravaginal estrogen targets genitourinary
syndrome of menopause (GSM) locally. No progestogen is needed as there
is no uterus .
Question 5
A 55-year-old woman has been on hormone therapy for 10 years and asks
about continuing. What is the most appropriate recommendation?
A) Continue indefinitely
B) Discuss risks and benefits and consider tapering
C) Switch to estrogen alone
D) Stop immediately due to breast cancer risk
Answer: B
Rationale: Long-term HT use requires ongoing risk-benefit assessment.
Shared decision-making about continuation or tapering is essential .
, Question 6
What is the "climacteric phase"?
A) The final menstrual period
B) The period of endocrinologic, somatic, and transitory psychologic
changes around the time of menopause
C) The perimenopause only
D) The postmenopausal period
Answer: B
Rationale: The climacteric phase is the period of endocrinologic, somatic,
and transitory psychologic changes that occur around the time of
menopause. It encompasses the transition from the reproductive stage to
the non-reproductive stage .
Question 7
Early menopause is defined as:
A) LMP before age 40
B) LMP before age 45
C) LMP before age 50
D) LMP after age 55
Answer: B
Rationale: Early menopause is defined as the last menstrual period (LMP)
occurring before age 45. It should be distinguished from primary ovarian
insufficiency (POI), which occurs before age 40 .
Question 8
According to the STRAW+10 staging system, what characterizes the "early
menopause transition" (stage –2)?
Certified Practice Questions with
Clinical Rationales — The Menopause
Society Certification Guide
PHYSIOLOGY & PATHOPHYSIOLOGY (Questions 1-50)
Question 1
A 52-year-old woman presents with persistent moderate hot flashes and
night sweats. She had a hysterectomy 5 years ago. She is currently on oral
conjugated equine estrogens (CEE) 0.3 mg daily but reports inadequate
symptom control. What is the most appropriate management?
A) Switch to transdermal estradiol 0.025 mg patch
B) Discontinue estrogen and start a selective serotonin reuptake inhibitor
C) Increase the daily estrogen dose
D) Add oral micronized progesterone 100 mg daily
Answer: C
Rationale: The patient is on the lowest FDA-approved dose of CEE (0.3 mg).
With persistent symptoms despite adequate treatment duration (typically
4-8 weeks), dose escalation is appropriate. The 0.3 mg dose may be
insufficient for symptom control in some women. Since she had a
hysterectomy, no progestogen is needed, simplifying dose adjustment .
,Question 2
Which agent is the best FDA-approved non-hormonal treatment for
moderate-to-severe vasomotor symptoms in a 55-year-old woman with a
history of estrogen receptor-positive breast cancer?
A) Venlafaxine
B) Gabapentin
C) Paroxetine
D) Black cohosh
Answer: C
Rationale: Systemic estrogen is contraindicated in breast cancer survivors.
Paroxetine 7.5 mg (Brisdelle) is FDA-approved specifically for VMS and is a
non-hormonal option with demonstrated efficacy. SSRIs/SNRIs are
preferred non-hormonal alternatives for breast cancer survivors; however,
paroxetine has the specific FDA approval for this indication .
Question 3
According to the Menopause Society guidelines, which strategy helps
reduce venous thromboembolism (VTE) risk in women using hormone
therapy?
A) Use low-dose oral estrogen
B) Use transdermal estrogen instead of oral
C) Add aspirin to the regimen
D) Use only progestogen therapy
Answer: B
Rationale: Transdermal estrogen avoids first-pass hepatic metabolism, has
lower impact on coagulation factors, and is associated with lower VTE risk
,compared to oral estrogen. VTE risk is dose-dependent and transdermal
routes are especially important in women with other VTE risk factors .
Question 4
A 46-year-old woman with a history of hysterectomy (ovaries remain)
presents with pain with intercourse but no other menopausal symptoms.
What is the best treatment?
A) Systemic hormone therapy with estrogen plus progestogen
B) Oral ospemifene
C) Intravaginal estrogen only
D) Systemic estrogen alone
Answer: C
Rationale: Symptoms are localized with no VMS. Ovaries remain, so
estrogen production continues. Intravaginal estrogen targets genitourinary
syndrome of menopause (GSM) locally. No progestogen is needed as there
is no uterus .
Question 5
A 55-year-old woman has been on hormone therapy for 10 years and asks
about continuing. What is the most appropriate recommendation?
A) Continue indefinitely
B) Discuss risks and benefits and consider tapering
C) Switch to estrogen alone
D) Stop immediately due to breast cancer risk
Answer: B
Rationale: Long-term HT use requires ongoing risk-benefit assessment.
Shared decision-making about continuation or tapering is essential .
, Question 6
What is the "climacteric phase"?
A) The final menstrual period
B) The period of endocrinologic, somatic, and transitory psychologic
changes around the time of menopause
C) The perimenopause only
D) The postmenopausal period
Answer: B
Rationale: The climacteric phase is the period of endocrinologic, somatic,
and transitory psychologic changes that occur around the time of
menopause. It encompasses the transition from the reproductive stage to
the non-reproductive stage .
Question 7
Early menopause is defined as:
A) LMP before age 40
B) LMP before age 45
C) LMP before age 50
D) LMP after age 55
Answer: B
Rationale: Early menopause is defined as the last menstrual period (LMP)
occurring before age 45. It should be distinguished from primary ovarian
insufficiency (POI), which occurs before age 40 .
Question 8
According to the STRAW+10 staging system, what characterizes the "early
menopause transition" (stage –2)?
